Stock AnalizUNITED THERAPEUTICS (UTHR) earnings for the quarter ended September 2026: EPS misses estimates
UNITED THERAPEUTICS reported results for the quarter ended September 2026 on November 4, 2026. Adjusted earnings per share came in at $5.71 against the analysts’ average forecast of $6.04, a miss of 5.5%.
Revenue for the quarter was $832 million, up 4.1% from $800 million in the same quarter a year earlier.
The market’s verdict: the stock fell 5.9% on the first trading day after the report.
The last four quarters
UNITED THERAPEUTICS has beaten the analysts’ EPS forecast in 2 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $5.71 | $6.04 | −5.5% | +4% | −5.9% |
| Jun 2026 | $7.27 | $6.86 | +6.0% | −2% | +2.8% |
| Mar 2026 | $5.82 | $6.86 | −15.1% | −2% | −0.5% |
| Dec 2025 | $7.70 | $6.76 | +14.0% | +7% | +6.4% |
What comes next
Analysts expect EPS of $4.46 for the next quarter on average and $24.96 for the fiscal year ending December 31, 2026.
The average analyst price target is $687.14, 16% above the current price of $591.17.
Valuation and score
UNITED THERAPEUTICS scores 4.0 out of 5 overall on Stock Analiz (a strong company), trades at a trailing P/E of about 22.3, and its intrinsic value under moderate assumptions is about 45% below the current market value. Full UNITED THERAPEUTICS analysis with 10 years of financials
Frequently asked questions
What was UNITED THERAPEUTICS’s EPS for the quarter ended September 2026?
$5.71 adjusted per share, against an analyst consensus of $6.04.
How much revenue did UNITED THERAPEUTICS report?
$832 million, up 4.1% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.